Literature DB >> 15882642

Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL.

Orhan Aktas1, Alina Smorodchenko, Stefan Brocke, Carmen Infante-Duarte, Ulf Schulze Topphoff, Johannes Vogt, Timour Prozorovski, Susanne Meier, Venera Osmanova, Elena Pohl, Ingo Bechmann, Robert Nitsch, Frauke Zipp.   

Abstract

Here, we provide evidence for a detrimental role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in neural death in T cell-induced experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Clinical severity and neuronal apoptosis in brainstem motor areas were substantially reduced upon brain-specific blockade of TRAIL after induction of EAE through adoptive transfer of encephalitogenic T cells. Furthermore, TRAIL-deficient myelin-specific lymphocytes showed reduced encephalitogenicity when transferred to wild-type mice. Conversely, intracerebral delivery of TRAIL to animals with EAE increased clinical deficits, while naive mice were not susceptible to TRAIL. Using organotypic slice cultures as a model for living brain tissue, we found that neurons were susceptible to TRAIL-mediated injury induced by encephalitogenic T cells. Thus, in addition to its known immunoregulatory effects, the death ligand TRAIL contributes to neural damage in the inflamed brain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882642     DOI: 10.1016/j.neuron.2005.03.018

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  66 in total

1.  The problems and promises of research into human immunology and autoimmune disease.

Authors:  Bart O Roep; Jane Buckner; Stephen Sawcer; Rene Toes; Frauke Zipp
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

Review 2.  [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].

Authors:  O Aktas; J Ingwersen; B Kieseier; P Küry; R Hohlfeld; H-P Hartung
Journal:  Nervenarzt       Date:  2011-02       Impact factor: 1.214

Review 3.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

Review 4.  Failed central nervous system regeneration: a downside of immune privilege?

Authors:  Ingo Bechmann
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

5.  Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions.

Authors:  Barbara Cannella; Stefanie Gaupp; Kakuri M Omari; Cedric S Raine
Journal:  J Neuroimmunol       Date:  2007-07-05       Impact factor: 3.478

6.  Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.

Authors:  Marjaneh Razmara; Brendan Hilliard; Azadeh K Ziarani; Ramachandran Murali; Srikanth Yellayi; Mustafa Ghazanfar; Youhai H Chen; Mark L Tykocinski
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

7.  The cellular response in neuroinflammation: The role of leukocytes, microglia and astrocytes in neuronal death and survival.

Authors:  Monica J Carson; J Cameron Thrash; Barbara Walter
Journal:  Clin Neurosci Res       Date:  2006-12

Review 8.  Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.

Authors:  Hui-Ming Gao; Jau-Shyong Hong
Journal:  Trends Immunol       Date:  2008-07-01       Impact factor: 16.687

9.  TRAIL limits excessive host immune responses in bacterial meningitis.

Authors:  Olaf Hoffmann; Josef Priller; Timour Prozorovski; Ulf Schulze-Topphoff; Nevena Baeva; Jan D Lunemann; Orhan Aktas; Cordula Mahrhofer; Sarah Stricker; Frauke Zipp; Joerg R Weber
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 10.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.